Abstract
The discovery of activating epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) has led to a shift in treatment paradigm for some patients with advanced disease. Mutations in exons 18-21 in the tyrosine kinase domain are associated with improved clinical outcomes following treatment with tyrosine kinase inhibitors (TKIs). The first-generation EGFR TKIs erlotinib and gefitinib are most effective in the presence of EGFR mutations (1).
Original language | English |
---|---|
Pages (from-to) | 553-555 |
Number of pages | 3 |
Journal | Journal of Thoracic Disease |
Volume | 4 |
Issue number | 6 |
DOIs | |
Publication status | Published - Dec 2012 |
Keywords
- CELL LUNG-CANCER
- TYROSINE KINASE INHIBITORS
- GEFITINIB
- MUTATIONS
- ERLOTINIB
- RESISTANCE
- MODELS
- GENE